leisure time -WSS

leisure time

author：leisure time 2025-10-03 00:22:10 - browse：8

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Texas Department of Public Safety speaks out on migrant abuse allegations

WSS

Abortion pill case raises question: who can sue the FDA?

Scientists boost immune system in aging mice by making it youthful

Driven by the pandemic, applicants flood public health schools

EF3 tornado rips through North Carolina amid extreme weather nationwide

Decaf coffee targeted by food safety group under obscure FDA rule

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

hotspot

leisure time

explore

Virginia high school admissions case could be legal follow

Tocagen's brain cancer gene therapy trial continues. Investors worry

Virginia high school admissions case could be legal follow

Why the world’s most expensive drug might be worth the price

Affirmative action in medical school literally saved lives

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Anesthesiologist group: stop taking Ozempic before surgery

Decaf coffee targeted by food safety group under obscure FDA rule

23andMe had bad news about my health. I wish a person had delivered it

Wildfires rage amid heat wave in Greece, prompting evacuations and call for European support

explore

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

Why the world’s most expensive drug might be worth the price

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Merck drug for rare lung condition set for approval in U.S.

Senate committee advances SCOTUS ethics bill after alleged justice misconduct

Readout LOUD podcast: mifepristone case, GLP

knowledge

hotspot

hotspot

hotspot